FILE PHOTO: The logo of Swiss drugmaker Novartis is seen at the company’s new cell and gene therapy factory in Stein, Switzerland, November 28, 2019.
Arnd Wiegmann | Reuters
Novartis shares tanked 10% on Tuesday after the pharmaceutical giant said its del-desiran drug for muscle-wasting disorder failed in a late-stage trial.
The company’s stock was last seen down by 10%, as investors reacted to what was its third drug trial setback in a week.
Novartis stock
This is a developing story. Please refresh for updates.
Please follow and like us:
